The PERFECTO consortium comprises five key partners dedicated to advancing cardiovascular health through Familial Hypercholesterolaemia (FH) screening. This diverse and well-balanced group brings together expertise from various fields, including health technology assessment, medical innovation, academic research, and public health advocacy. Led by FH Europe Foundation, the consortium also includes the EuroScan network for HTA (Germany), Centre for Innovation in Medicine (Romania), Cyprus University of Technology (Cyprus), and the European Public Health Alliance (International). Supporting these core partners are a Scientific Exchange Group, a Multi-disciplinary Reflection Group, and a Health Economics Expert Group, with additional collaboration from experts in Ukraine and Bulgaria.
Meet our partners who are driving the implementation of FH paediatric screening and contributing to the reduction of cardiovascular disease burden across Europe.
The Foundation’s main focus is advocacy and patient support, it drives public health policy improvements and collaborates progressively with leading European and the EU institutions – like the European Commission, the European Parliament and many other EU stakeholders. FH Europe Foundation is the next stage in the evolution of FH Europe (fheurope.org), the European Network of FH patient organisations. FH Europe and its Network has a leading place in the European public health policy space responding to the unmet needs of patients and people affected with inherited lipid conditions. FH Europe member patient organisation in Bulgaria will play an active role in testing/ validating materials and outputs from WP3. FH Europe is aware that the Bulgarian health system has implemented cholesterol screening at age 16. Building on this, Bulgaria aspires to implement a fully-fledged FH Paediatric Screening Programme, which could leverage the results and learnings from PERFECTO.
The network acquired legal status in 2017, becoming EuroScan International Network e. V., a not-for-profit scientific association registered in Germany connecting public agencies, scientific organisations and individuals across all continents. EuroScan has been and aims to remain the main global forum for sharing and developing of methods for early identification and pre-assessment of emerging, new, and obsolete health technologies. EuroScan membership comprises several organisations around the world including members in four continents but mainly based in Europe (NIHR UK, Agenas IT, Osteba SP, AETSA SP, NIPHNO NO, Inca FR) and Asia Pacific (MaHTAs Ma, NECA SK, Singapore HTA, CDN TW; Australia and New Zealand). EuroScan holds a MoU with several organisations including WHO, HTAi; INAHTA, HTAsiaLink and REDETSA. EuroScan has been collaborating in several EU funded projects among those it can be mentioned the active Horizon 2020 SAFENMEDTECH (https://safenmt.com/ ) and the IMI EU-PEARL (https://eu-pearl.eu/).
CUT is the second largest and one of the leading research Universities in Cyprus, that has high values regarding its academic character and its emphasis on high quality research in major branches of science and technology. It has a staff of approximately 300 academics, approximately 400 Researchers and Special Scientists, and 219 administrative employees supporting all aspects of teaching and research. Research emphasis at CUT is reflected in the substantial funding provided to academics for the establishment of research centres and laboratories, the support it provides for collaborations with world renowned Universities and Institutions, and the participation of its faculty in several national and European research projects. The University is pioneering in the production of applied research and achieving excellence in the international research area. In order to meet the challenges of society and industry, the results of the research produced at the University are transferred as know-how to society, industry and productive organisations to create innovative solutions with significant economic, social and environmental benefits. In the context of research, innovation and entrepreneurship activities, new jobs and opportunities are created for young scientists in cutting-edge sectors.
InoMed is a non-governmental organisation based in Bucharest, with a focus on innovation in healthcare. It aims to shorten the time between the emergence of innovations in the medical sector and their application for patients' benefit in Romania and elsewhere. The Center develops programs to educate, inform and engage all audiences about innovation in medicine to create a friendly environment for early adoption of innovative technologies, ideas, products and services. InoMed also serves as an independent platform for informed dialogue between stakeholders in the field of omics medicine, personalised (precision) medicine, digital health, data oncology, immune-oncology, cancer research, biotechnology, systems biology and other hot scientific topics. InoMed is active in dedicated communication, education, advocacy and policy channels but also research activities.
A member-led organisation made up of public health NGOs, patient groups, health professionals and disease groups, we work to improve health and strengthen the voice of public health in Europe. EPHA has a solid network of 80 members dedicated to providing better health for all across the EU, through umbrella organisations and national members. Together with them, EPHA advocates for public health solutions leading to better health for all based on its values of equity, solidarity, sustainability, universality, diversity and good governance. Through its Roma Health Network, EPHA is also one of the leading NGO alliances for the voice in Roma health.
